Table 3.
Effect of crocin and losartan on histopathology of kidney tissue
| Variable % | Groups | ||||
|---|---|---|---|---|---|
| U | D | DC | DL | DLC | |
| Mesangioproliferative glomerulopathy | 0.0 | 58.32±3.63*# | 36.45±3.5*# | 33.32±3.63*# | 29.75±2.48*# |
| Tubular cell glycogen storage | 3.11±1.51 | 85.74±4.71*# | 41.66±3.85*# | 52.38±5.37*# | 36.9±3.08*# |
| Tubular cell necrosis & desquamation | 1.09±1.03 | 38.09±4.4*# | 27.07±1.35*# | 28.55±1.67*# | 28.55±1.67*# |
| Tubulointerstitial Congestion | 8.31±2.72 | 51.18±5.27*# | 27.07±2.08*# | 29.75±2.48*# | 29.75±4*# |
| Tubulointerstitial Inflammation | 3.11±1.52 | 39.28±3.51*# | 22.92±2.07*# | 28.58±3.57*# | 23.8±3.36*# |
Data is mean percentage±SEM, N=8, U (untreated control), D (Diabetic), DC (Diabetic treated with crocin), DL (Diabetic treated with losartan), and DLC (Diabetic treated with losartan and crocin). *p<0.05 significant difference compared with the group U, #p<0.05 significant difference compared with the group D.